Calamos Advisors
ADPT icon

Calamos Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Calamos Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58,808
Closed -$816K – 983
2026
Q1 		$816K Sell
58,808
-125,216
-68% -$1.99M ﹤0.01% 820
2025
Q4 		$2.99M Sell
184,024
-26,253
-12% -$428K 0.01% 586
2025
Q3 		$3.15M Sell
210,277
-4,328
-2% -$52.7K 0.01% 594
2025
Q2 		$2.5M Buy
214,605
+73,716
+52% +$670K 0.01% 617
2025
Q1 		$1.05M Buy
+140,889
New +$1.08M ﹤0.01% 645

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Calamos Advisors's ADPT Position: Q2 2026 in Review

Calamos Advisors sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 58,808 shares — an estimated $816K sold.

Calamos Advisors first reported a position in ADPT in Q1 2025 and held it in 5 quarters. The position peaked at $3.15M in Q3 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Calamos Advisors reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Calamos Advisors sold 58,808 Adaptive Biotechnologies shares in Q2 2026, an estimated $816K.
  • Calamos Advisors first reported a position in Adaptive Biotechnologies in Q1 2025 and held it in 5 quarters.
  • Calamos Advisors's Adaptive Biotechnologies position peaked at $3.15M in Q3 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.